Quest Diagnostics Incorporated ($DGX)

HR8260 is a procedural early-stage bill with zero funding authorization and no market-moving catalyst. No price action has been observed in LH ($260.86) or DGX ($193.96) related to this legislation. The bill has only been referred to committee; passage probability is low at this time.

→ This would expand the addressable testing population for cardiovascular risk markers, driving incremental lab test volume for DGX's commercial and government payer books.

The Combating Illicit Xylazine Act (S545) is a drug scheduling bill that reclassifies xylazine as a Schedule III controlled substance. It authorizes no new funding, tax incentives, or procurement programs, resulting in negligible market impact for retail-investor-relevant publicly traded companies.

HR 3037 (Access to Breast Cancer Diagnosis Act) is an early-stage bill eliminating patient cost-sharing for diagnostic breast exams. The bill benefits diagnostic imaging providers $DGX and $LH through higher utilization, while insurers face increased claims costs. Passage is uncertain at this procedural stage, but bipartisan cosponsorship and a companion Senate bill signal moderate legislative momentum.

→ Removal of cost-sharing reduces the financial barrier for patients to schedule diagnostic breast imaging (e.g., diagnostic mammograms, ultrasound, MRI). This is expected to increase utilization volumes for these exams as the out-of-pocket cost deterrent is eliminated.

S.3607 expands Medicare Part B to cover genetic counseling as a new provider category effective Jan 1, 2027, directly increasing the addressable patient population for genetic testing. This is a structural positive for Labcorp ($LH) and Quest Diagnostics ($DGX) through higher test volume, and for AMN Healthcare ($AMN) through increased demand for scarce genetic counselors. The bill is at early legislative stage (referred to Finance Committee) with companion bill HR6280 in the House.

→ Same mechanism as for LH: Medicare coverage of genetic counselor services removes a referral bottleneck, increasing the volume of genetic test orders from Medicare beneficiaries; genetic counselors will have a direct incentive to order companion diagnostic tests after counseling sessions

HR6897 (Thyroid Disease CARE Act) authorizes $30M/year for five years for thyroid disease research and improved diagnostics. The bill is in early stage — referred to House Energy and Commerce Committee on December 18, 2025. Real market data shows diagnostic stocks trending negative over the past 30 days, with Labcorp down 1.53% and Abbott down 11.85%. Any impact is procedural and speculative at this stage.

→ Federal grants and contracts will be issued for thyroid disease diagnostic research and improved diagnostic techniques

The SCREENS for Cancer Act reauthorizes and expands national cancer screening programs for 2026-2030. This creates a structural volume tailwind for Labcorp ($LH) and Quest Diagnostics ($DGX) as the primary processors of screening lab work. Both stocks have been down over the past month on broader market weakness, not bill-specific news — the authorization provides a real federal program pipeline for incremental testing revenue once appropriations are secured.

→ Increased volume of breast and cervical cancer screening lab tests reimbursed through the program, which serves over 6.4M people historically and is expected to expand

The RESULTS Act (S.2761) proposes shifting Medicare Part B lab test payment rate data collection from CMS to an independent nonprofit, targeting the key revenue risk for $LH and $DGX under PAMA. The bill is early-stage (referred to committee) and faces a multi-year path, but its mechanism directly addresses a structural headwind that has driven ~10% cumulative Medicare rate cuts since 2018. Real market data shows a 5-day selloff in both tickers — $LH dropped from $270.68 to $263.99 and $DGX from $195.02 to $195.64 — creating an entry point for investors betting on legislative momentum for reimbursement stability.

→ Shifts the data source used to calculate private payor-based fee schedule rates from a CMS-mandated reporting system (which has led to steep, unpredictable rate cuts) to a qualified independent nonprofit database. This reduces the risk of CMS-administrative errors and data-weighting imbalances that have caused 10-15% cumulative PAMA cuts since 2018.

HR3482 is a procedural authorization bill requiring the VA to build an online scheduling system for community care appointments. It mandates an IT system change but includes no explicit funding, and it does not directly increase patient volume or reimbursement rates. The market impact on healthcare stocks ($DGX, $LH, $HCA, $UHS, $AMN) is negligible in the near term.

S. 800 (Precision Brain Health Research Act of 2025) expands the VA's biomarker research mandate but authorizes zero new funding. The bill is reported out of committee and awaiting floor action. Labcorp ($LH at $262.63) and Quest Diagnostics ($DGX at $194.98) show no legislative catalyst in their recent price trends—both are down ~0.5-1.6% over the last 30 days. No near-term market impact.

→ VA research expansion creates a potential procurement need for biomarker testing, but without appropriations it is a legislative authorization only—no contract dollars obligated.

HR2004 'Tyler’s Law' is a procedural early-stage bill directing HHS to study fentanyl testing in emergency departments. It authorizes zero funding, imposes no mandates, and has languished in committee for over a year with no further action, producing no near-term market impact for any public company.

HR6178, introduced in November 2025 and referred to two committees, mandates no-cost lung cancer screenings and expanded tobacco cessation services under Medicaid, Medicare, and private insurance. This creates a direct revenue tailwind for diagnostic lab companies $LH and $DGX through increased test volume, and a pharmacy/PBM benefit for $CVS through mandated tobacco cessation drug coverage. Health insurers ($UNH, $HUM, $CNC, $MOH) face a neutral cost burden from the coverage mandate and prior authorization ban, with manageable MLR impact given the preventive nature of the service. The bill is early-stage with no appropriation attached.

→ Same structural increase in diagnostic testing volume as LH. The bill creates a fedearally mandated market expansion for lung cancer screening and follow-up testing services across both public and private insurance populations.

The SUPPORT for Patients and Communities Reauthorization Act (P.L. 119-44) became law on December 1, 2025, extending federal substance use disorder and mental health funding through FY2030. This creates a structural tailwind for diagnostic testing (LH, DGX) and pharmaceutical distribution (CAH) via sustained grant programs, while also providing a positive policy backdrop for psychedelic therapy developers (CMPS, MNMD). Recent market data shows diagnostic stocks declining over the past 30 days, with LH at $261.79 (-1.88% 30d) and DGX at $193.52 (-1.26% 30d), suggesting the market has not yet priced in this long-term authorization catalyst.

→ Renewed federal funding for opioid-related testing panels and infectious disease surveillance testing sustains demand for Quest's clinical laboratory services over the FY2026–2030 period.

HR1406 (Lung Cancer Screening and Prevention Act of 2025) would expand Medicare coverage to FDA-approved lung cancer screening tests beyond the current USPSTF-recommended set. The bill is in early committee stage with no authorized funding, limiting near-term market impact. GEHC, LH, and DGX are structural beneficiaries if passed, but passage is uncertain and distant.

→ CMS must set coverage and payment limits for additional lung cancer screening tests; screening volumes for diagnostic imaging and lab testing increase as Medicare beneficiaries gain access to a broader set of FDA-cleared tests

HR7868, the 'Expanding Support for Living Donors Act of 2026,' is an early-stage bill authorizing up to $10,000 per donor for qualifying expenses in FY2027. Actual appropriations are required. The market reaction in diagnostic ($LH, $DGX) and device ($MDT, $SYK) stocks is currently driven by broader market trends — all four stocks are down 2-9% over the past 30 days — not by this bill's introduction. The legislative impact on revenue is negligible at this stage.

→ Increased volume of donor pre-screening and post-operative diagnostic lab tests reimbursed under the program, potentially raising test utilization by living donors

The 'Supporting Healthy Moms and Babies Act' (HR3762) is an early-stage bill that would mandate comprehensive maternity/newborn care coverage without cost-sharing under ACA plans. With 28 cosponsors, a companion bill in the Senate, and referral to three committees, legislative progress is early but has nominal bipartisan support. Insurers UNH and CI face increased medical costs, while diagnostic labs LH and DGX benefit from higher utilization. No dollar amount is authorized or appropriated.

→ Higher volume for Quest Diagnostics' core laboratory business from patient-facing pregnancy-related testing (prenatal screening, NIPT, carrier status, postpartum monitoring).

The RESULTS Act (HR5269) is an early-stage bill aiming to stabilize Medicare reimbursement for clinical diagnostic lab tests by improving data accuracy. It has 77 cosponsors and a companion bill in the Senate but remains in committee with no near-term market impact. Real market data shows LH at $259 and DGX at $190.19, both down ~3% over 30 days, reflecting sector headwinds unrelated to this procedural legislation.

→ the bill modifies data collection requirements for widely available non-advanced diagnostic lab tests, potentially altering the data inputs that determine the weighted median private payor rate used to set Medicare payment for these tests

The ASAP Act (HR6130) mandates Medicare coverage for FDA-cleared blood-based dementia screening tests starting Jan 1, 2028. Labcorp ($LH) and Quest Diagnostics ($DGX) are the two largest independent lab operators with existing FDA-cleared blood-based dementia tests, making them primary beneficiaries of this new mandatory benefit category. The bill is in early legislative stages (referred to committee) with companion bill S3267 in the Senate, but the bipartisan sponsorship and 82 cosponsors indicate strong momentum for a mid-2027 passage timeline.

→ Quest Diagnostics, which markets its own blood-based dementia test (AD-Detect, measuring amyloid beta 42/40 ratio and apolipoprotein E), gains Medicare reimbursement for a test currently covered only by private payors and cash-pay patients. This opens a large new volume channel in the Medicare population.

The CHOICE for Veterans Act of 2025 (HR3132) is awaiting floor action after being reported out of committee. This bill expands fee agreements for VA benefits claims, which is expected to improve claims efficiency and reimbursement rates for healthcare providers serving veterans. Companies like HCA Healthcare ($HCA), Universal Health Services ($UHS), Labcorp Holdings ($LH), and Quest Diagnostics ($DGX) are positioned to benefit from these operational improvements.

→ Increases revenue opportunities for legal and claims assistance services, leading to more efficient and potentially higher quality claim submissions for VA benefits. This improves the likelihood and speed of reimbursement for healthcare providers.

The Find It Early Act (S.1410), introduced in April 2025, would mandate no-cost-sharing coverage for advanced breast imaging for high-risk individuals and those with dense breast tissue. The bill is in early legislative stages (referred to committee) with no funding authorized. Real market data shows GEHC has fallen 14.88% in the last 7 days to $59.49, near its 52-week low, while UNH has surged 41.62% over 30 days to $370.74—moves driven by factors unrelated to this early-stage bill.

→ Quest Diagnostics' advanced imaging and radiology service volume increases as the eligible population (high-risk + dense breast tissue) receives no-cost access. The elimination of out-of-pocket costs drives utilization among price-sensitive patients.

The Reducing Hereditary Cancer Act (HR4752) mandates Medicare coverage for germline mutation testing—a direct expansion of the addressable market for genetic diagnostics companies. The bill is in early committee stage (referred to Energy & Commerce and Ways & Means), with a Senate companion bill (S2760) also introduced. Real market data shows genetic testing/ diagnostics tickers have declined 0.09% to 5.12% in the past week, but this bill represents structural demand expansion independent of recent price action.

→ Test volume for Quest's hereditary cancer panels increases among Medicare beneficiaries.